|
Robin
Good thought to remind us of the P85 angle. Susan Love's site does mention that the Her2 receptor in some women can be "damaged" or non functioning. P85 could be responsible for that. However, if the receptor is different (or deformed and herceptin does not fit in lock and key) does the protein (which is also a lock and key mechanism)? According to some literature (and a reference to that on the Love site), individuals with deformed receptors don't have the same (negative) Her2 prognosis. (Then one has to think that if those with deformed receptors have nothing to worry about but were in the early herceptin adjuvant trials, then, theorically they would not recur as readily since the Her2 mechanism was not relevent. And if they were hormone positive and on a hormonal, that would be all they needed. However, if they were hormone negative and Her 2 could not be their problem, then something else was driving their cancer to grow. Hence, some recurrences may not be due to Her2 and early herceptin could be working better than we think.
Just talking out loud here.
Have a great Saturday night.
Becky
|